New 6-Month TB drug cocktail could replace Year-Long ordeal
NCT ID NCT07486024
First seen Jun 27, 2026 · Last updated Sep 17, 2026 · Updated 2 times
Summary
This study tests a new 6-month treatment called BPaLM for people with multidrug-resistant tuberculosis (MDR-TB). The goal is to see if it works as well as the current 18+ month regimen. About 55 adults in France will receive the shorter treatment, and their outcomes will be compared to past patients who had standard care. If effective, this could greatly reduce treatment burden and improve quality of life for MDR-TB patients.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- BPaLM regimen (bedaquiline, pretomanid, linezolid, moxifloxacin)
- What this could lead to
- If successful, this could offer a much shorter, more tolerable treatment for multidrug-resistant tuberculosis, replacing the current long and difficult regimen.
- What could go wrong
- This is a small, non-randomized trial comparing to historical data, so results may not be conclusive. The regimen still requires careful monitoring for side effects like nerve damage or heart issues.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 3
Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.
- Participants
-
About 55 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Sep 2026
- Expected to finish
-
Feb 2032
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion criteria 1. Is 18 years old or more 2. Is affected by bacteriologically- or molecularly-confirmed tuberculosis, due to strains of M. tuberculosis resistant to rifampicin (with or without resistance to isoniazid) according to a rapid molecular test 3. Is willing and able to give informed consent to be enrolled in the research project (signed or witnessed consent if the patient is illiterate) 4. Patients seen in consultation or hospitalized in one of the centers involved for rifampicin-resistant TB, with screening results available and compatible within 14 days following consent signature; 5. Is willing to use effective\* contraception: women with childbearing potential\*\* must agree to use effective contraception, unless their partner has had a vasectomy, for the duration of study treatment and up to 6 months after the end of study treatment; men who have not had a vasectomy must agree to use effective contraception for the duration of study treatment and up to 3 months after the end of study treatment; * The following contraception methods are considered effective, according to local regulation (CTFG recommendations, March 2024): 1. Combined hormonal contraception (oestrogen + progestin) 2. Progestin-only hormonal contraception 3. Intrauterine device (IUD) 4. Intrauterine hormone-releasing system (IUS) 5. Bilateral tubal occlusion 6. Vasectomised partner * A woman is considered of childbearing potential (WOCBP), i.e. fertile, following menarche and until becoming post-menopausal unless permanently sterile. Permanent sterilisation methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy. A postmenopausal state is defined as no menses for 12 months without an alternative medical cause. A high follicle stimulating hormone (FSH) level in the postmenopausal range may be used to confirm a post-menopausal state in women not using hormonal contraception or hormonal replacement therapy. However in the absence of 12 months of amenorrhea, a single FSH measurement is insufficient. 6. Is affiliated to a social security system (as beneficiary) or has state medical aid (AME) or has an ongoing demand for AMEor has an ongoing demand for an emergency medical care (dispositif de soins d'urgence, as applicable for tuberculosis) Exclusion criteria : 1. Is unable to take oral drugs 2. Has known allergies, hypersensitivity or intolerance or any other medical condition and contra indications to any drug of the regimen 3. Unwilling to comply to study procedures, at the clinician appreciation 4. Has proven or likely resistance to bedaquiline, clofazimine, linezolid, pretomanid or moxifloxacine, or has had exposure (for 30 days or more) in past five years to bedaquiline, clofazimine, delamanid, linezolid, or pretomanid 5. Is taking or needs to take contraindicated medications in association with investigational medicinal products 6. Has ≥500 msec QTcF interval on any ECG taken at screening or baseline visits, or has any cardiac risk factor for severe arrhythmia 7. Has severe extrapulmonary TB, including meningo-encephalitis, brain abscess, osteo-arthritis, osteomyelitis 8. Is concurrently participating in another trial of any medicinal product 9. Is already on a MDR/RR-TB treatment regimen since 4 weeks or more, and has no need to change the treatment regimen (i.e. adverse events, treatment failure) 10. Has significant and uncorrectable lab abnormalities at baseline: haemoglobin ≤7.9 g/dL, platelet count \<75 000/mm3; absolute neutrophil count \<1 000/ mm3; potassium \<3.0 mEq/L; serum creatinine \>3 x upper level of normality (ULN); alanine aminotransferase (ALT) ≥3 x ULN 11. Has peripheral neuropathy of grade 3 or 4 (CTCAE scale) 12. Has any other condition (social or medical) which, in the opinion of the site investigator, would make the study participant unsafe 13. Is known to be pregnant or is unwilling or unable to stop breastfeeding an infant 14. Individuals permanently legally incompetent adults, under judicial or administrative protection and vulnerable persons
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Antibiotic resistance are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
5 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
CHU Amiens
RECRUITINGAmiens, France
-
CHU Bichat - Claude-Bernard
RECRUITINGParis, 75018, France
-
CHU Rennes
RECRUITINGRennes, France
-
CHU Toulouse - Hôpital Purpan
RECRUITINGToulouse, 31059, France
-
Pitié-Salpêtrière Hospital - infectious and tropical diseases
NOT_YET_RECRUITINGParis, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Antibiotic resistance fight: can a website change how doctors prescribe?
- Can newer tests match the gold standard for detecting Drug-Resistant TB?
- Can a new antibiotic combo beat Drug-Resistant urinary infections in the blood?
- New 6-Month drug cocktail aims to tame resistant TB
- Superbug sleuths decode the DNA of drug-resistant e. coli to stop its spread
- Sputum DNA test aims to outsmart Drug-Resistant TB